Read the case and answer 5 questions. Each answer gives immediate feedback.
NovaChem Industries, a 60-year-old specialty chemicals manufacturer, is facing existential pressure. New environmental regulations require a 40% reduction in carbon emissions within five years. Simultaneously, two agile competitors have entered the market offering bio-based alternatives at lower cost, and NovaChem’s top talent has begun exiting to join start-ups with clearer sustainability missions.
The Board appoints a new CEO, Dr. Sofia Maren, with a mandate to transform the company. Dr. Maren’s diagnostic review reveals: Strategy misalignment (the current 5-year plan doesn’t address sustainability), a rigid hierarchical structure that slows decision-making, a culture of compliance rather than innovation, and a leadership team with strong technical expertise but weak change-leadership capabilities.
Dr. Maren proposes a three-phase transformation: Phase 1 — diagnose and create urgency; Phase 2 — redesign strategy, structure, and build capability; Phase 3 — embed new culture and governance. She faces significant resistance from middle management who fear losing their authority in the flattened structure. The Board supports her but warns that financial pressures demand results within 18 months.